NEW YORK, Feb. 4 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc.
(Nasdaq: EMIS), a biopharmaceutical company that focuses on a unique and
improved delivery of therapeutic molecules using its eligen(R) technology,
today announced that the company will present at the BIO CEO & Investor
Conference on February 12, 2008 at the Waldorf Astoria Hotel in New York
City.
Michael V. Novinski, President and Chief Executive Officer of
Emisphere, will present for the company at 2:45 PM in the Lexington Suite
of the Hotel. Gary Riley, BVSc, MVSc, Vice President, Nonclinical
Development and Applied Biology, will co-present.
For more information on the BIO CEO & Investor Conference, including
registration, hotel accommodations and an up-to-date program, please visit
the conference Web site at http://ceo.bio.org/opencms/ceo/2008/index.jsp.
About Emisphere Technologies, Inc.
Emisphere Technologies, Inc. is a biopharmaceutical company that
focuses on a unique and improved delivery of therapeutic molecules using
its eligen(R) technology. These molecules and compounds could be currently
available or in development. Such molecules are usually delivered by
injection; in many cases, their benefits are limited due to poor
bioavailability, slow on-set of action or variable absorption. The
eligen(R)technology can be applied to the oral route of administration as
well other delivery pathways, such as buccal, rectal, inhalation,
intra-vaginal or transdermal. The web site is: http://www.emisphere.com.
Safe Harbor Statement Regarding Forward-Looking Statements
The statements in this release and oral statements made by
representatives of Emisphere relating to matters that are not historical
facts (including without limitation those regarding future performance or
financial results, the timing or potential outcomes of research
collaborations or clinical trials, any market that might develop for any of
Emisphere's product candidates and the sufficiency of Emisphere's cash and
other capital resources) are forward-looking statements that involve risks
and uncertainties, including, but not limited to, the likelihood that
actual performance or results could materially differ, that future research
will prove successful, the likelihood that any product in the research
pipeline will receive regulatory approval in the United States or abroad,
the ability of Emisphere and/or its partners to develop, manufacture and
commercialize products using Emisphere's drug delivery technology, or
Emisphere's ability to fund such efforts with or without partners.
Emisphere undertakes no obligation to update any of these statements.
Readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as to the date hereof. Accordingly any
forward-looking statements should be read in conjunction with the
additional risks and uncertainties detailed in Emisphere's filings with the
Securities and Exchange Commission, including those factors discussed under
the caption "Risk Factors" in Emisphere's Annual Report on Form 10-K (file
no. 000-17758) filed on March 6, 2007, and our Quarterly Report on Form
10-Q for the quarter ended March 31, 2007, filed on May 7, 2007 (file no.
000-17758) and for the quarter ended June 30, 2007, filed on August 7, 2007
(file No. 000-17758).
SOURCE Emisphere Technologies, Inc.
 back to top
Related links:
http://www.emisphere.com
CONTACT:
Bob Madison, Senior Director Corporate
Communications, Emisphere Technologies, Inc., +1-973-532-8001; or
Adam Friedman, Adam Friedman Associates, +1-212-981-2529, ext. 18
|
